Lixte Z Score

LIXT -  USA Stock

USD 2.150.010.47%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Additionally, see Lixte Biotech Piotroski F Score and Lixte Biotech Valuation analysis.

Lixte Z Score Analysis

Lixte Biotech's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 Z Score = Sum Of 5 Factors
More About Z Score | All Equity Analysis

Current Lixte Biotech Z Score

-19.6
Most of Lixte Biotech's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotech Hlds is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 First Factor = 1.2 * ( Working Capital / Total Assets )
 Second Factor = 1.4 * ( Retained Earnings / Total Assets )
 Thrid Factor = 3.3 * ( EBITAD / Total Assets )
 Fouth Factor = 0.6 * ( Market Value of Equity / Total Liabilities )
 Fifth Factor = 0.99 * ( Revenue / Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
 Compare to competition Predict Lixte Biotech
Based on the company's disclosures, Lixte Biotech Hlds has a Z Score of -19.6. This is 390.37% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The z score for all United States stocks is notably higher than that of the company.

Lixte Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotech's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotech could also be used in its relative valuation, which is a method of valuing Lixte Biotech by comparing valuation metrics of similar companies.
Lixte Biotech is currently under evaluation in z score category among related companies.

Lixte Biotech Institutional Holders

Institutional Holdings refers to the ownership stake in Lixte Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lixte Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotech's value.
 Security Type Shares Value Almanack Investment Partners Llc Common Shares 982 K 3 M Santa Monica Partners Lp Common Shares 166.7 K 505 K Vanguard Group Inc Common Shares 74.4 K 225 K Morgan Stanley Common Shares 71.1 K 215 K Sabby Management Llc Common Shares 65.5 K 199 K Renaissance Technologies Llc Common Shares 50.9 K 154 K Sabby Management Llc Warrants 140.1 K 107 K State Street Corp Common Shares 33.6 K 102 K

Lixte Fundamentals

 Return On Equity (95.04) % Return On Asset (56.61) % Current Valuation 35.93 M Shares Outstanding 13.54 M Shares Owned by Insiders 67.85 % Shares Owned by Institutions 9.80 % Number of Shares Shorted 29.88 K Price to Earning (2.96) X Price to Book 17.54 X Price to Sales 28.72 X Revenue 200 K Net Income (4.61 M) Cash and Equivalents 7.74 M Cash per Share 0.57 X Debt to Equity 0.16 % Current Ratio 32.55 X Book Value Per Share 0.12 X Cash Flow from Operations (2.74 M) Short Ratio 0.06 X Earnings Per Share (0.29) X Beta -1.08 Market Capitalization 28.97 M Total Asset 1.38 M Retained Earnings (19.54 M) Working Capital 1.24 M Current Asset 1.38 M Current Liabilities 140 K Z Score -19.6

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotech Hlds's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotech Hlds based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Our tools can tell you how much better you can do entering a position in Lixte Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
 All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lixte Biotech Hlds using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Lixte Biotech Piotroski F Score and Lixte Biotech Valuation analysis. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
 Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format Go Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments Go Risk-Return AnalysisView associations between returns expected from investment and the risk you assume Go Watchlist OptimizationOptimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm Go Stock ScreenerFind equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. Go Shere PortfolioTrack or share privately all of your investments from the convenience of any device Go Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios Go Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum Go Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets Go Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum Go Transaction HistoryView history of all your transactions and understand their impact on performance Go Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets Go Technical AnalysisCheck basic technical indicators and analysis based on most latest market data Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.